Whole Exome Sequencing Identifies Two Novel Mutations in a Patient with UC Associated with PSC and SSA

Dong Wu,1,2 Dan Chen,1 Wen Shi,1 Wei Liu,3 Weixun Zhou,4 and Jiaming Qian1

1Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China
2Center for Rare Diseases Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China
3Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China
4Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing 100730, China

Correspondence should be addressed to Weixun Zhou; zhouwx@pumch.cn and Jiaming Qian; wudong@pumch.cn

Received 11 March 2021; Accepted 24 August 2021; Published 11 September 2021

Academic Editor: Yu-Chen Fan

Copyright © 2021 Dong Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Patients diagnosed with ulcerative colitis (UC) associated with primary sclerosing cholangitis (PSC) and sessile serrated adenoma (SSA) are rare. The present study aimed to identify the potential causative gene mutation in a patient with UC associated with PSC and SSA. Methods. DNA was extracted from the blood sample and tissue sample of SSA, followed by the whole exome sequencing (WES) analysis. Bioinformatics analysis was utilized to predict the deleteriousness of the identified variants. Multiple sequence alignment and conserved protein domain analyses were performed using online software. Sanger sequencing was used to validate the identified variants. Expression and diagnostic analysis of identified mutated genes was performed in the GSE119600 dataset (peripheral blood samples of PSC and UC) and GSE43841 dataset (tumors samples of SSA).

Results. In the present study, a total of 842 single nucleotide variants (SNVs) in 728 genes were identified in the blood sample. Two variants, integrin beta 4 (ITGB4) (c.C2503G; p.P835A) and a mucin 3A (MUC3A) (c.C1019T; p.P340L), were further analyzed. MUC3A was associated with inflammatory bowel disease. Sanger sequencing in blood revealed that the ITGB4 mutation was fully cosegregated with the result of WES in the patient. Additionally, a variant, tumor protein p53 gene (TP53) (c.86delA; p.N29Tfs*15) was identified in the tissue sample of SSA. Compared to that in normal controls, ITGB4 was upregulated in both UC and PSC, MUC3A was, respectively, upregulated and downregulated in PSC and UC, and TP53 was downregulated in SSA. ITGB4 and TP53 had a potential diagnostic value for UC, PSC and SSA.

Conclusions. The present study demonstrated that the ITGB4 (c.C2503G; p.P835A) and MUC3A (c.C1019T; p.P340L) mutations may be the potential causative variants in a patient with UC associated with PSC and SSA. TP53 (c.86delA; p.N29Tfs*15) mutation may be associated with SSA in this patient.

1. Background

Primary sclerosis cholangitis (PSC) is a chronic disease with inflammation and fibrotic obliteration of the intra and extrahepatic bile duct, which can lead to bile stasis and hepatic fibrosis [1, 2]. PSC is associated with underlying inflammatory bowel disease (IBD), mainly ulcerative colitis (UC) [1]. There is no effective medical treatment for this condition, and liver transplantation represents the treatment of choice for patients with end-stage [3]. In Western countries, approximately 52–90% of patients with PSC have concurrent UC [4–8]. Meanwhile, the number of patients with UC, as well as with other types of IBDs, continues to increase in Western countries [9, 10]. Several current reports suggest that patients with PSC associated with UC (PSC-UC) have increased gradually in some European populations [11]. The involvement of gut bacteria in PSC-UC patients is widely accepted [12, 13]. Accumulating evidence suggested that gut
dysbiosis and abnormal bile acid metabolites are involved in PSC [14]. However, the pathogenetic mechanism of PSC is far from clear. Furthermore, patients with PSC-IBD have an increased risk of colon cancer and cholangiocarcinoma compared with those with IBD alone [15].

Sessile serrated adenomas (SSA) give rise to 20–30% of colorectal cancer (CRC). SSA displays endoscopic features which present challenges in diagnosis and surveillance. SSA are increasingly found in colectomy specimens from CRC patients. SSA differs from conventional adenomas in several respects. They arise at any age and are over represented in young patients [5, 6]. Histologically, they vary little in appearance for the majority of their dwell time prior to the development of dysplasia. However, once dysplasia develops, SSA rapidly progresses to CRC [7]. SSA are thought to be responsible for “interval” CRCs which arise within the colonoscopy surveillance interval [7]. Genetic factors that contribute to development of SSA are not well understood, but microsatellite instability (MSI) is thought to be involved. Rajagopalan et al. [16] used the HumanMethylation 450 array to identify methylated genes in SSA compared with normal mucosa, followed by RNA sequencing. Three genes were methylated and downregulated in SSA, including bone morphogenetic protein 3 (BMP3), erythrocyte membrane protein band 4.1 like 3 (EPB41L3), and cystathionine beta-synthase (CBS). Using a customised methylation microarray, Beach et al. [17] identified 32 genes which were methylated in SSAs compared with normal mucosa and performed immunohistochemistry for the six most promising candidates.

Whole exome sequencing (WES) is widely used to explore the genetic mechanism of rare diseases [18–20]. The present study investigated a patient with UC associated with PSC and SSA. The results on the inheritance of mutant genes may provide novel information regarding the pathological mechanism underlying this unusual condition.

2. Methods

2.1. Patients. For the purpose of this study, a patient with UC associated with PSC and SSA was recruited. The diagnosis of UC was made due to clinical symptoms, endoscopic examination, and biopsy of the colon mucosa. The diagnosis of PSC was based on radiological imaging and liver biopsy. The diagnosis of SSA was based on endoscopic features and histological investigation. The patient’s peripheral blood was collected. Genomic DNA was extracted for WES. The tissue sample of SSA from a colonoscopy biopsy was also used for WES analysis. Our study was approved by the Research Ethics Committee of the Peking Union Medical College Hospital (approval number 2603, 2898). The written informed consent was obtained from this patient before the study.

2.2. Analysis of Exome Capture. The genomic DNA was extracted from the blood sample according to the standard procedures. The 3 μg of genomic DNA was fragmented with approximately 200 bp, ligated with adapters, and amplified by ligation-mediated polymerase chain reaction (PCR). The qualified genomic DNA was used for exome capture and high-throughput sequencing. SureSelect XT Library Prep Kit was used to perform exome target enrichment. The captured library was sequenced on the Illumina HiSeq X-Ten sequencer with paired-end 125 bp and mean coverage of 200x [21].

2.3. Analysis of Basic Biological Information. The FastQC and SeqPrep were utilized to detect the quality of primary data of exome sequencing. Raw data were filtered by removing the adapter, contaminating reads and low-quality reads via SeqPrep and sickle, and the remains were the clean ones. The exome sequencing clean reads were mapped to the reference human genome sequence (hg19) (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips/) using the Burrows–Wheeler Alignment (BWA) tool (http://bio-bwa.sourceforge.net/bwa.shtml), which can do short reads alignment to a reference genome and support paired-end mapping. The sequence alignment/map (SAM) file was then generated. Picard tool (http://picard.sourceforge.net/) was used to mark and exclude the duplicate reads. Variants (single nucleotide variants (SNVs), insertions, and deletions) calling was performed using the Genome Analysis Toolkit (GATK) [22].

2.4. Functional Annotation of Hotspot Mutation Genes. In order to investigate the biological function of hotspot mutation genes, 73 hotspot mutation genes were analyzed in the Gene Ontology (GO) functional categories, the Online Mendelian Inheritance in Man (OMIM), and the Kyoto Encyclopedia of Genes and Genomes (KEGG) biochemical pathway using the GeneCodis3 (http://genecodis.cnb.csic.es/analysis).

2.5. Sanger Sequencing for Variant Validation. After the systematic filtering, two candidate variants ITGB4 (c.C2503G; p.P835A) and MUC3A (c.C1019T; p.P340L) were selected for variant validation. Genomic DNA was prepared from the patient. After oligonucleotide primer was designed by using Primer-Premier 5.0 (Premier Biosoft International, Palo Alto, CA, USA). PCR analyses and Sanger sequencing were then performed. The amplification process was 15 min at 95°C followed by 40 cycles of 10 sec at 95°C, 30 sec at 55°C, 32 sec at 72°C, and 15 sec at 95°C, 60 sec at 60°C, and 15 sec extension at 95°C. The PCR products were used for Sanger sequencing.

2.6. In Silico Analysis. The multiple sequence alignment of ITGB4 and TAS2R46 in different species was performed using an online tool (https://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?LINK_LOC=BlastHomeLink). In addition, Conserved Domain Search Service (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) was used to identify the conserved protein domains.
2.7. Expression and Diagnostic Analysis of Mutated Genes. The GSE119600 dataset (peripheral blood samples, involving 45 PSC cases, 93 UC cases, and 47 normal controls) and GSE43841 dataset (tumor samples, involving 6 SSA cases and 6 normal controls) were used for expression and diagnostic analysis of mutated genes. The ROC analysis was used to assess the diagnostic value of mutated genes. The expression result of mutated genes was shown by box plots.

3. Results

3.1. Clinical Manifestations. At present study, one male patient (63 years old) who was diagnosed with UC associated with PSC and SSA was included in the study. He had bloody diarrhea and lower abdominal pain for 8 years before admission. On colonoscopic examination, diffuse edema, erosion, and petechial hemorrhage were noted along the whole colon and rectum. The diagnosis of UC was made based on clinical, endoscopic, and histological data. A flat polyp with a size of 0.6 cm was detected in the cecum and was resected (Figure 1). Histological diagnosis of SSA was made according to serrated hyperplasia and basal dilitation of crypts (Figure 2). PSC was diagnosed based on radiological image (Figure 3) and liver biopsy (Figure 4(a)). Histological examination demonstrated neutrophilic microabscesses in the crypts and infiltration with mononuclear cells and plasma cells in the lamina propria (Figure 4(b)). Figure 4(a) discloses onion skin-like changes, lymphocyte infiltration plasmacytes, and scattered eosinophils with fibrosis and pseudolobulation. Two portal areas had hyperplastic ductule.

3.2. Genetic and In Silico Analysis. Genomic DNA samples in the blood sample from the patient were analyzed. A total of 842 single nucleotide variants (SNVs) in 728 genes were identified. Among which, 26 genes had three or more rare missense mutations, and 47 genes had two rare missense mutations. Based on the WES in the patient and subsequent Sanger sequencing results, 6 SNVs, the c.C2503G mutation (a substitution from P to L) in TAS2R46, the c.T869A mutation (a substitution from F to L) in HLA-A, and the c.C3414A mutation (a substitution from D to E) in MUC16 were likely to be associated with UC associated with PSC and SSA. In the tissue sample of the patient when diagnosed with SSA, TP53 mutation (c.86delA; p.N29fs*15) (Chr17: 7579710) was identified. Interestingly, the missense mutation of ITGB4, MUC3A, and TP53 is found in the tumor tissue of CRC in the Cancer Genome Atlas (TCGA) dataset (involving 471 CRC cases and 41 normal controls). It is suggested that mutations of ITGB4, MUC16, and TP53 are significantly associated with both SSA and CRC (Supplementary Figure 1).

3.3. Functional Annotation of 73 Hotspot Mutation Genes. In Supplementary Figure 2, based on the GO, KEGG, and OMIM enrichment analyses, TAS2R31, TAS2R46, and TAS2R43 were significantly enriched in taste transduction (FDR = 0.005854). MUC3A was associated with inflammatory bowel disease 11 (FDR = 0.004677). MUC5B was associated with pulmonary fibrosis idiopathic (FDR = 0.013961). HLA-A was associated with severe cutaneous adverse reaction and (FDR = 0.028276) spondyloarthropathy (FDR = 0.028276). ITGB4 was involved in epidermolysis bullosa simplex (FDR = 0.008169).

3.4. In Silico Analysis. The c.C2503G mutation in ITGB4 resulted in a protein alteration of p.P835A. In addition, the c.A0664T mutation in MUC16 resulted in a protein alteration of p.P13555L. Furthermore, it was highly conserved across several species, including humans, Macaca mulatta, Mus musculus, Ovis aries, and Castor canadensis (Figure 5). Furthermore, the amino acid at position 13555 in the MUC16 protein sequence was located in the SEA domain, and it was highly conserved across several species, including humans, Pan troglodytes, Cricetus griseus, Eumetopias jubatus, and Theropithecus gelada (Figure 6).

3.5. Sanger Sequencing of the Candidate Causative Variants. In order to further confirm the c.C2503G mutation in UC associated with PSC and SSA, Sanger sequencing was performed on the patient. The results demonstrated that the c.C2503G mutation in ITGB4 was fully cosegregated with patient recruited for WES (Figure 7).

3.6. Expression and Diagnostic Analysis of Mutated Genes. First, we investigated the expression of ITGB4 and MUC3A in peripheral blood of UC and PSC in the GSE119600 dataset and the expression of TP53 in tumor of SSA the GSE43841 dataset (Figure 8). The result showed that ITGB4 was upregulated in both UC and PSC, compared to that in normal controls. MUC3A was upregulated in PSC and downregulated in UC, compared to that in normal controls. TP53 was downregulated in SSA, compared to that in normal controls. It is suggested that mutation of above genes may be associated with gene expression. Second, we performed the ROC analysis to evaluate the diagnostic value of ITGB4, MUC3A, and TP53 (Figure 9). The ROC result showed that the AUC of ITGB4 and TP53 was more than 0.6, which suggested that they had a diagnostic value for UC, PSC, and SSA.

4. Discussion

Patients who were diagnosed with UC associated with PSC and SSA were clinically rare. UC is currently affecting more than 3.5 million people in Europe and North America [23]. The disease is recrudescent, and the main symptoms during a relapse are diarrhea, rectal bleeding, and abdominal pain [24]. Approximately every 20 patients with IBD are affected by PSC, a chronic bile duct disease characterized by oblitative fibrosis. This is an incurable, progressive condition associated with an increased risk of cholangiocarcinoma and colon cancer [25, 26]. At present, genetic mechanisms
Figure 1: Flat polyp with subtle margin at the cecum ((a) white light; (b) indigo carmine).

Figure 2: Serrated hyperplasia of the crypts and basal dilation of some crypts, consistent with SSA.

Figure 3: Multiple stricture and dilation of intrahepatic bile ducts.

Figure 4: (a) Liver biopsy revealing portal infiltration of lymphocytes, plasmacytes, and scattered eosinophils with fibrosis and pseudolobule (H&E, 10×10). (b) Histological examination demonstrating neutrophilic microabscesses in the crypts (H&E, 10×20).
underlying UC associated with PSC pathogenesis remain to be fully elucidated. As previously reported, David Ellinghaus identified two novel risk loci, G protein-coupled receptor 35 (GPR35) and transcription factor 4 (TCF4), at genome-wide significance levels. GPR35 shows associations in both UC and PSC, whereas TCF4 represents a PSC risk locus not associated with UC [27]. WES technology is an effective method for identifying potential causative genes in disease phenotypes [28]. In the present study, WES was performed to identify potential causative genes in the patient who was diagnosed with UC associated with PSC and SSA. Two mutations (c.C2503G and c.C1019T) in ITGB4 and MUC3A genes, respectively, were revealed to be associated with UC associated with PSC and SSA. MUC3A was associated with inflammatory bowel disease. In addition, Sanger sequencing validated ITGB4 mutation in the patient.

Our result demonstrated the crucial role of MUC3A in the development of UC associated with PSC and SSA. Mucins are classified into 11 membrane-bound mucins and 7 secreted mucins. Analogous to MUC3A, MUC1, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20, and MUC21 are all membrane-bound mucins [29]. Membrane-bound mucins share conserved domains, such as sea urchin sperm protein enterokinase and agrin (SEA) domains or

Figure 5: (a) Affected amino acid residue of ITGB4 highly conserved between different species. (b) Conserved domains in fatty acid synthase.

Figure 6: (a) Affected amino acid residue of MUC16 highly conserved between different species. (b) Conserved domains in fatty acid synthase.
Figure 7: Sanger validation results of ITGB4 variant in the patient with UC associated with PSC and SSA. Arrow represents the mutation site.

Figure 8: Expression box plots of ITGB4, MUC3A, and TP53 in peripheral blood of UC and PSC and TP53 in tumor of SSA in the GSE43841 dataset.

Figure 9: The ROC curves of ITGB4 and MUC3A in UC and PSC and TP53 in SSA.
epidermal growth factor-like (EGF). Due to their localization and structure at the cell surface, they may participate in cell signaling, cell-matrix, and cell-cell interactions, modulating and structure at the cell surface, they may participate in cell proliferation through growth factors [31]. Poor prognosis with abnormal high cysteine-rich epidermal growth factor-like (EGF). Due to their localization in appendiceal, and prostate cancer [32–37]. Zimmer et al. identified in the tissuesample of the patient when diagnosed with SSA. Moreover, TP53 was downregulated in tumor of SSA. It is supposed that mutation of TP53 may be related to the expression level of TP53. Significantly, TP53 had a potential diagnostic value for SSA, which is considered as a diagnostic biomarker for SSA. TP53 plays an important role in senescence or apoptosis in cells with damaged genomes [49]. The association between TP53 mutations and IBD-associated CRC has been reported [50]. A higher frequency of TP53 mutation is found in UC-CRC compared to sporadic CRC. An increase in the frequency of TP53 in the bile of PSC patients with the malignancy has been demonstrated. In addition, subsets of serrated adenomas showed TP53 mutation. Our study indicated that the TP53 (c.86delA; p.N29Tfs*15) mutation may be associated with disease progression of UC associated with PSC and SSA.

In conclusion, mutations in ITGB4 (c.C2503G; p.P835A) and MUC3A (c.C1019T; p.P340L) may predispose patients with UC to PSC and SSA. MUC3A is associated with inflammatory bowel disease. These findings may reveal the high degree of genetic heterogeneity in patient with UC associated with PSC and SSA. Additionally, TP53 (c.86delA; p.N29Tfs*15) may be regarded as a risk diagnostic factor for patients developed to SSA. Future work will be performed to improve understanding of this disorder. However, there is a limitation of the present study. First, the sample size is small. Larger peripheral blood and tumor samples from patients with UC associated with PSC and SSA are further needed for analysis. Second, identified mutations are further needed to be verified in colon tumors or precancerous lesions. Third, the in vitro study is further needed to verify the molecular biological changes caused by mutations, such as cell proliferation, dedifferentiation, and tumorigenesis phenotype of intestinal epithelium in cell lines or animal models. Fourth, analysis of gut dysbiotics and differential metabolites is further needed to study in PSC.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by the Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing,
**Supplementary Materials**

Supplementary Figure 1: distribution of mutated genes (ITGB4, MUC16, and TP53) in SSA and CRC. Supplementary Figure 2: significantly enriched GO terms and KEGG pathways of 73 hotspot mutation genes. The size of the spot indicated counts of mutation genes enriched in GO terms or KEGG pathways, and the color of the spot indicates the FDR/significance level of the enriched pathways or GO terms. (Supplementary Materials)

**References**

[1] K. N. Lazaridis and N. F. LaRusso, “Primary sclerosing cholangitis,” *New England Journal of Medicine*, vol. 375, no. 12, pp. 1161–1170, 2016.

[2] M. Lampinen, J. Vessby, A. Fredricsson, A. Wanders, F. Rorsman, and M. Carlson, “High serum sCD40 and a distinct colonic T cell profile in ulcerative colitis associated with primary sclerosing cholangitis,” *Journal of Crohn’s and Colitis*, vol. 13, no. 3, pp. 341–350, 2019.

[3] J. Kumagai, T. Taida, S. Ogasawara et al., “Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients,” *PLoS One*, vol. 13, no. 12, Article ID e0209352, 2018.

[4] T. J. Weismüller, P. J. Trivedi, A. Bergquist et al., “Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis,” *Gastroenterology*, vol. 152, no. 8, pp. 1075.e8–1084.e8, 2017.

[5] K. Boonstra, R. K. Weersma, K. J. van Erpecum et al., “Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis,” *Hepatology*, vol. 58, no. 6, pp. 2045–2055, 2013.

[6] J. J. W. Tischendorf, H. Hecker, M. Krüger, M. P. Manns, and P. N. Meier, “Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study,” *American Journal of Gastroenterology*, vol. 102, no. 1, pp. 107–114, 2007.

[7] A. F. Gulamhusein, J. E. Eaton, J. H. Tabibian, E. J. Atkinson, B. D. Juran, and K. N. Lazaridis, “Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD,” *American Journal of Gastroenterology*, vol. 111, no. 5, pp. 705–711, 2016.

[8] J. Ø. Sørensen, O. H. Nielsen, M. Andersen et al., “Inflammatory bowel disease with primary sclerosing cholangitis: a Danish population-based cohort study 1977–2011,” *Liver International*, vol. 38, 2018.

[9] G. G. Kaplan and S. C. Ng, “Understanding and preventing the global increase of inflammatory bowel disease,” *Gastroenterology*, vol. 152, no. 2, pp. 313.e2–321.e2, 2017.

[10] N. A. Molodecky, I. S. Soon, D. M. Rabi et al., “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review,” *Gastroenterology*, vol. 142, no. 1, pp. 46.e2–54.e2, 2012.

[11] C. Nordenvall, O. Olén, P. J. Nilsson et al., “Colecotomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients,” *Alimentary Pharmacology & Therapeutics*, vol. 47, no. 2, pp. 238–245, 2018.

[12] L. Bajer, M. Kverka, M. Kostovcik et al., “Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis,” *World Journal of Gastroenterology*, vol. 23, no. 25, pp. 4548–4558, 2017.

[13] M. Kummene, K. Holme, J. A. Anmarkrud et al., “The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls,” *Gut*, vol. 66, no. 4, pp. 611–619, 2017.

[14] R. Little, E. Wine, B. M. Kamath, A. M. Griffiths, and A. Ricciuto, “Gut microbiome in primary sclerosing cholangitis: a review,” *World Journal of Gastroenterology*, vol. 26, no. 21, pp. 2768–2780, 2020.

[15] N. Razumilav, G. J. Gores, and K. D. Lindor, “Cancer surveillance in patients with primary sclerosing cholangitis,” *Hepatology*, vol. 54, no. 5, pp. 1842–1852, 2011.

[16] H. Rajagopalan, A. Bardelli, C. Lengauer, K. W. Kinzler, B. Vogelstein, and V. E. Velculescu, “RAF/RAS oncogenes and mismatch repair status,” *Nature*, vol. 418, no. 6901, pp. 934, 2002.

[17] R. Beach, A. O-O. Chan, T.-T. Wu et al., “BRAF mutations in aberrant crypt foci and hyperplastic polyposis,” *American Journal of Pathology*, vol. 166, no. 4, pp. 1069–1075, 2005.

[18] M. J. Bamshad, S. B. Ng, A. W. Bigham et al., “Exome sequencing as a tool for mendelian disease gene discovery,” *Nature Reviews Genetics*, vol. 12, no. 11, pp. 745–755, 2011.

[19] S. B. Ng, E. H. Turner, P. D. Robertson et al., “Targeted capture and massively parallel sequencing of 12 human exomes,” *Nature*, vol. 461, no. 7261, pp. 272–276, 2009.

[20] J. L. Wang, X. Yang, K. Xia et al., “TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing,” *Brain*, vol. 133, no. 12, pp. 3510–3518, 2010.

[21] Y. Ye and Y. Zeng, “Whole exome sequencing identifies a novel intron heterozygous mutation in TSC2 responsible for tuberous sclerosis complex,” *Scientific Reports*, vol. 9, no. 1, pp. 4456, 2019.

[22] A. McKenna, M. Hanna, E. Banks et al., “The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data,” *Genome Research*, vol. 20, no. 9, pp. 1297–1303, 2010.

[23] M. Lampinen, A. Fredricsson, J. Vessby et al., “Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis,” *Journal of Leukocyte Biology*, vol. 104, no. 1, pp. 173–183, 2018.

[24] G. G. Kaplan, “The global burden of IBD: from 2015 to 2025,” *Nature Reviews Gastroenterology & Hepatology*, vol. 12, no. 12, pp. 720–727, 2015.

[25] U. Broumé and A. Bergquist, “Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer,” *Seminars in Liver Disease*, vol. 26, pp. 31–41, 2006.

[26] A. Rönblom, T. Holmström, H. Tanghöj, F. Rorsman, and D. Sjöberg, “Appearance of hepatobiliary diseases in a population-based cohort with inflammatory bowel diseases (inflammatory bowel disease cohort of the Uppsala region),” *Journal of Gastroenterology and Hepatology*, vol. 30, no. 8, pp. 1288–1292, 2015.

[27] D. Ellingshaus, T. Folseaas, K. Holm et al., “Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4,” *Hepatology*, vol. 58, no. 3, pp. 1074–1083, 2013.

[28] J. Sun, L. Sun, W. Chen, X. Yin, Y. Lu, and Q. Jiang, “A family with hypothyroidism caused by fatty acid synthase and apolipoprotein B receptor mutations,” *Molecular Medicine Reports*, vol. 18, pp. 4904–4912, 2018.
S. Yonezawa, M. Higashi, N. Yamada et al., "Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application," *Pathology International*, vol. 61, no. 12, pp. 697–716, 2011.

N. Jonckheere, N. Skrypek, F. Frénois, and I. Van Seuningen, "Membrane-bound mucin modular domains: from structure to function," *Biochimie*, vol. 95, no. 6, pp. 1077–1086, 2013.

J. R. Gum Jr, J. L. Ho, W. S. Pratt et al., "MUC3 human intestinal mucin," *Journal of Biological Chemistry*, vol. 272, no. 42, pp. 26678–26686, 1997.

T. J. Duncan, N. F. Watson, A. H. Al-Attar, J. H. Scholefield, and L. G. Durrant, "The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer," *World Journal of Surgical Oncology*, vol. 5, no. 1, p. 31, 2007.

H.-U. Park, J.-W. Kim, G. E. Kim et al., "Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl lex antigen in pancreatic intraepithelial neoplasia," *Pancreas*, vol. 26, no. 3, pp. e48–e54, 2003.

E. A. Rakha, R. W. G. Boyce, D. Abd El-Rehim et al., "Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer," *Modern Pathology*, vol. 18, no. 10, pp. 1295–1304, 2005.

R.-Q. Wang and D. C. Fang, "Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features," *Journal of Clinical Pathology*, vol. 56, no. 5, pp. 378–384, 2003.

H. Shibahara, M. Higashi, S. Yokoyama et al., "A comprehensive expression analysis of mucins in appendiceal carcinoma in a multicenter study: MUC3 is a novel prognostic factor," *PLoS One*, vol. 9, no. 12, Article ID e115613, 2014.

G. S. Arul, M. Moorghen, N. Myerscough, D. A. Alderson, R. D. Spicer, and A. P. Corfield, "Mucin gene expression in Barrett’s oesophagus: an in situ hybridisation and immunohistochemical study," *Gut*, vol. 47, no. 6, pp. 753–761, 2000.

K.-P. Zimmer, M. Heine, G. Weissen-Plenz, K. A. Scholand, H. Herbst, and H. Y. Naim, "TGF -associated MUC2 and MUC3 expression of the gastric epithelium in menetrier’s disease during remission of ulcerative colitis," *Gut*, vol. 60, no. 11, pp. 1607-1608, 2011.

H. Kim, Y. Chung, S. S. Paik, K. Jang, and S.-J. Shin, "Mesothelin expression and its prognostic role according to microsatellite instability status in colorectal adenocarcinoma," *Medicine*, vol. 98, no. 26, Article ID e16207, 2019.

J. S. Golia Pernicka, J. Gagniere, J. Chakraborthy et al., "Radiomics-based prediction of microsatellite instability in colorectal cancer at initial computed tomography evaluation," *Abdominal Radiology*, vol. 44, no. 11, pp. 3755–3763, 2019.

L. Xiao, F. Wei, F. Liang et al., "TSG22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole-exome sequencing," *Carcinogenesis*, vol. 40, no. 7, pp. 819–827, 2019.

Y. Nakayama, T. Iijima, R. Wakaume et al., "Microsatellite instability is inversely associated with type 2 diabetes mellitus in colorectal cancer," *PLoS One*, vol. 14, no. 4, Article ID e0215513, 2019.

F. Innocenti, F.-S. Ou, X. Qu et al., "Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome," *Journal of Clinical Oncology*, vol. 37, no. 14, pp. 1217–1227, 2019.

T. Yoshioka, J. Otero, Y. Chen et al., "Ã¥4 integrin signaling induces expansion of prostate tumor progenitors," *Journal of Clinical Investigation*, vol. 123, pp. 682–699, 2013.